Clinical trials: Influenza Virus
Influenza
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK…
- Trial name
- NCT01196988
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 59 sites in United States, Czechia and 3 more
- Volunteers
- 3,027 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to < 12 years with influenza…
- Trial name
- NCT06774859
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Influenza
Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation
This study is in support of the annual application for the variation of the vaccine strains for a marketing authorization. Objectives: To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split…
- Trial name
- NCT00946179
- Testing
- Influenza virus (split virion, inactivated) vaccine
- Where
- 2 sites in Switzerland
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of Quadrivalent Influenza Vaccine Among Adults
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the investigational TIV containing the alternate…
- Trial name
- NCT01218646
- Testing
- Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
- Where
- 12 sites in United States
- Volunteers
- 739 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses
The aim of this study will be to evaluate the efficacy of regular cleaning of the oropharynx (via gargling) on the incidence of symptoms associated with flu and colds.
- Trial name
- NCT06479226
- Testing
- cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Influenza, Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HI) at 21 days post…
- Trial name
- NCT00956449
- Testing
- Seasonal Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India
The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India: Primary objective: To describe in each age group the immune…
- Trial name
- NCT02451358
- Testing
- Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative
- Where
- 8 sites in India
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines
This project aims to test the hypothesis that oral consumption of a specific strain of the probiotic bacterium Lactobacillus fermentum (trademarked PCC®) is able to significantly enhance the immune response to a vaccine for…
- Trial name
- NCT00294788
- Testing
- Fluvax, PCC® (Lactobacillus fermentum VRI 003)
- Where
- Australia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Probiomics Ltd
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study.
- Trial name
- NCT02658409
- Testing
- GC3106(quadrivalent cell-culture based influenza vaccine), Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)
- Where
- South Korea
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension
This study will evaluate the safety, efficacy and pharmacokinetics of Suraxavir Marboxil compared with oseltamivir in Pediatric Patients (2 to <12 Years) with Uncomplicated Influenza.
- Trial name
- NCT07113392
- Testing
- Suraxavir Marboxil, Oseltamivir
- Volunteers
- 144 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Common Cold
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as…
- Trial name
- NCT06531707
- Testing
- Ibuprofen + Loratadine fixed dose, Ibuprofen, Loratadine
- Where
- Mexico
- Volunteers
- 177 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Influenza, Healthy
D2560C00015 FluMist Annual Safety Study 2018
This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.
- Trial name
- NCT03564444
- Testing
- Bivalent influenza vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)
The objective of this study is to assess the safety, tolerability and immunogenicity of a Split Virus, Vero Cell derived, Seasonal Influenza Vaccine (VCIV) in comparison to a Licensed Egg Derived, Split Virus, Seasonal Influenza…
- Trial name
- NCT00424086
- Testing
- Inactivated seasonal influenza vaccine (split virus, vero cell derived), Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Pandemic Influenza A (H1N1), A New Flu Virus of Swine Origin
Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine
This is an observational safety study of a prophylactic use of Flu Egg Derived Adjuvanted Swine Origin A(H1N1) Vaccine in subjects 6 months of age and older.
- Trial name
- NCT01040741
- Testing
- Non-intervention observational study
- Where
- 14 sites in Argentina, Netherlands
- Volunteers
- 7,284 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.
- Trial name
- NCT00851266
- Testing
- V512
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
As a result of the safety and immunogenicity data generated from earlier dose-ranging studies, the present formulation has been selected for further development in the elderly.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00388583
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine
- Where
- 17 sites in United States
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
This is an open, randomized, multicenter clinical trial. Objectives: To describe the safety profiles during the 21 days following each primary and booster injection.
- Conditions
- Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection
- Trial name
- NCT00491985
- Testing
- A/H5N1 Inactivated, split-virion pandemic influenza vaccine, A/H5N1 Inactivated, split virion pandemic influenza vaccine
- Where
- Thailand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
The purpose of this study is to determine the safety and efficacy of TCN-032 given to healthy adult volunteers that have been inoculated with the influenza A virus
- Trial name
- NCT01719874
- Testing
- TCN-032
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Theraclone Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.